Do analysts rate GCTK or MBAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, GCTK or MBAI?

Check-Cap is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GlucoTrack N/A N/A -$19.39M -$18.04 N/A Check-Cap N/A N/A $4.14M -$2.77 N/A

Is GCTK or MBAI more profitable?

Check-Cap's return on equity of 0.00% beat GlucoTrack's return on equity. Company Net Margins Return on Equity Return on Assets GlucoTrack N/A -581.98% -220.10% Check-Cap N/A N/A N/A

Do analysts prefer GCTK or SINT?

Sintx Technologies has a consensus price target of $9.33, suggesting a potential upside of 386.11%. Given Sintx Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Sintx Technologies is more favorable than GlucoTrack. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sintx Technologies 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Do analysts prefer GCTK or QNRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, GCTK or QNRX?

Quoin Pharmaceuticals is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GlucoTrack N/A N/A -$19.39M -$18.04 N/A Quoin Pharmaceuticals N/A N/A -$15.81M -$29.56 N/A

Is GCTK or QNRX more profitable?

Quoin Pharmaceuticals' return on equity of -489.85% beat GlucoTrack's return on equity. Company Net Margins Return on Equity Return on Assets GlucoTrack N/A -581.98% -220.10% Quoin Pharmaceuticals N/A -489.85% -221.29%

Do analysts prefer GCTK or ALUR?

Allurion Technologies has a consensus price target of $45.00, suggesting a potential upside of 7,658.62%. Given Allurion Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Allurion Technologies is more favorable than GlucoTrack. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Allurion Technologies 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate NXL or GCTK?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

GlucoTrack (GCTK) Competitors

$0.36 +0.00 (+0.14%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$0.36 0.00 (-0.93%)

As of 06/23/2026 07:58 PM Eastern

Compare

GCTK vs. MBAI, SINT, QNRX, ALUR, and NXL

Should you buy GlucoTrack stock or one of its competitors? MarketBeat compares GlucoTrack with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GlucoTrack include Check-Cap (MBAI), Sintx Technologies (SINT), Quoin Pharmaceuticals (QNRX), Allurion Technologies (ALUR), and Nexalin Technology (NXL). These companies are all part of the "medical equipment" industry.

How does GlucoTrack compare to Check-Cap?

GlucoTrack (NASDAQ:GCTK) and Check-Cap (NASDAQ:MBAI) are both small-cap medical equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

In the previous week, Check-Cap had 1 more articles in the media than GlucoTrack. MarketBeat recorded 1 mentions for Check-Cap and 0 mentions for GlucoTrack. GlucoTrack's average media sentiment score of 0.00 equaled Check-Cap'saverage media sentiment score.

Company	Overall Sentiment
GlucoTrack	Neutral
Check-Cap	Neutral

Check-Cap's return on equity of 0.00% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GlucoTrack	N/A	-581.98%	-220.10%
Check-Cap	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Check-Cap is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlucoTrack	N/A	N/A	-$19.39M	-$18.04	N/A
Check-Cap	N/A	N/A	$4.14M	-$2.77	N/A

GlucoTrack has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, Check-Cap has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market.

10.9% of GlucoTrack shares are owned by institutional investors. Comparatively, 1.1% of Check-Cap shares are owned by institutional investors. 2.2% of GlucoTrack shares are owned by insiders. Comparatively, 0.5% of Check-Cap shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Check-Cap beats GlucoTrack on 5 of the 9 factors compared between the two stocks.

How does GlucoTrack compare to Sintx Technologies?

GlucoTrack (NASDAQ:GCTK) and Sintx Technologies (NASDAQ:SINT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

Sintx Technologies has a consensus price target of $9.33, suggesting a potential upside of 386.11%. Given Sintx Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Sintx Technologies is more favorable than GlucoTrack.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sintx Technologies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Sintx Technologies had 1 more articles in the media than GlucoTrack. MarketBeat recorded 1 mentions for Sintx Technologies and 0 mentions for GlucoTrack. GlucoTrack's average media sentiment score of 0.00 equaled Sintx Technologies'average media sentiment score.

Company	Overall Sentiment
GlucoTrack	Neutral
Sintx Technologies	Neutral

10.9% of GlucoTrack shares are owned by institutional investors. Comparatively, 18.4% of Sintx Technologies shares are owned by institutional investors. 2.2% of GlucoTrack shares are owned by insiders. Comparatively, 4.1% of Sintx Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

GlucoTrack has a net margin of 0.00% compared to Sintx Technologies' net margin of -1,058.60%. Sintx Technologies' return on equity of -366.49% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GlucoTrack	N/A	-581.98%	-220.10%
Sintx Technologies	-1,058.60%	-366.49%	-115.04%

Sintx Technologies has higher revenue and earnings than GlucoTrack. Sintx Technologies is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlucoTrack	N/A	N/A	-$19.39M	-$18.04	N/A
Sintx Technologies	$1.02M	8.13	-$10.36M	-$5.07	N/A

GlucoTrack has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market. Comparatively, Sintx Technologies has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

Summary

Sintx Technologies beats GlucoTrack on 11 of the 14 factors compared between the two stocks.

How does GlucoTrack compare to Quoin Pharmaceuticals?

GlucoTrack (NASDAQ:GCTK) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

Quoin Pharmaceuticals' return on equity of -489.85% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GlucoTrack	N/A	-581.98%	-220.10%
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%

GlucoTrack has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.56, meaning that its share price is 56% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

10.9% of GlucoTrack shares are owned by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. 2.2% of GlucoTrack shares are owned by company insiders. Comparatively, 13.5% of Quoin Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Quoin Pharmaceuticals is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlucoTrack	N/A	N/A	-$19.39M	-$18.04	N/A
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A

In the previous week, Quoin Pharmaceuticals had 2 more articles in the media than GlucoTrack. MarketBeat recorded 2 mentions for Quoin Pharmaceuticals and 0 mentions for GlucoTrack. GlucoTrack's average media sentiment score of 0.00 equaled Quoin Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
GlucoTrack	Neutral
Quoin Pharmaceuticals	Neutral

Summary

Quoin Pharmaceuticals beats GlucoTrack on 7 of the 11 factors compared between the two stocks.

How does GlucoTrack compare to Allurion Technologies?

GlucoTrack (NASDAQ:GCTK) and Allurion Technologies (NYSE:ALUR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

In the previous week, Allurion Technologies had 4 more articles in the media than GlucoTrack. MarketBeat recorded 4 mentions for Allurion Technologies and 0 mentions for GlucoTrack. GlucoTrack's average media sentiment score of 0.00 beat Allurion Technologies' score of -0.18 indicating that GlucoTrack is being referred to more favorably in the media.

Company	Overall Sentiment
GlucoTrack	Neutral
Allurion Technologies	Neutral

Allurion Technologies has a consensus price target of $45.00, suggesting a potential upside of 7,658.62%. Given Allurion Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Allurion Technologies is more favorable than GlucoTrack.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Allurion Technologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

GlucoTrack has a net margin of 0.00% compared to Allurion Technologies' net margin of -199.96%. Allurion Technologies' return on equity of 0.00% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GlucoTrack	N/A	-581.98%	-220.10%
Allurion Technologies	-199.96%	N/A	-77.13%

Allurion Technologies has higher revenue and earnings than GlucoTrack. Allurion Technologies is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlucoTrack	N/A	N/A	-$19.39M	-$18.04	N/A
Allurion Technologies	$17.21M	0.51	-$7.20M	-$2.03	N/A

10.9% of GlucoTrack shares are held by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are held by institutional investors. 2.2% of GlucoTrack shares are held by insiders. Comparatively, 8.1% of Allurion Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

GlucoTrack has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market. Comparatively, Allurion Technologies has a beta of -0.13, meaning that its stock price is 113% less volatile than the broader market.

Summary

Allurion Technologies beats GlucoTrack on 11 of the 15 factors compared between the two stocks.

How does GlucoTrack compare to Nexalin Technology?

Nexalin Technology (NASDAQ:NXL) and GlucoTrack (NASDAQ:GCTK) are both small-cap medical equipment companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

0.7% of Nexalin Technology shares are owned by institutional investors. Comparatively, 10.9% of GlucoTrack shares are owned by institutional investors. 25.3% of Nexalin Technology shares are owned by insiders. Comparatively, 2.2% of GlucoTrack shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Nexalin Technology had 3 more articles in the media than GlucoTrack. MarketBeat recorded 3 mentions for Nexalin Technology and 0 mentions for GlucoTrack. Nexalin Technology's average media sentiment score of 0.36 beat GlucoTrack's score of 0.00 indicating that Nexalin Technology is being referred to more favorably in the media.

Company	Overall Sentiment
Nexalin Technology	Neutral
GlucoTrack	Neutral

Nexalin Technology has a beta of 3.8, suggesting that its stock price is 280% more volatile than the broader market. Comparatively, GlucoTrack has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market.

GlucoTrack has a net margin of 0.00% compared to Nexalin Technology's net margin of -3,018.12%. Nexalin Technology's return on equity of -191.88% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-3,018.12%	-191.88%	-166.43%
GlucoTrack	N/A	-581.98%	-220.10%

Nexalin Technology has higher revenue and earnings than GlucoTrack. Nexalin Technology is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$300K	24.70	-$8.22M	-$0.47	N/A
GlucoTrack	N/A	N/A	-$19.39M	-$18.04	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Nexalin Technology beats GlucoTrack on 9 of the 12 factors compared between the two stocks.

Get GlucoTrack News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GCTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GCTK vs. The Competition

Export

Metric	GlucoTrack	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.28M	$8.08B	$6.44B	$12.39B
Dividend Yield	N/A	2.60%	2.69%	5.83%
P/E Ratio	-0.02	15.24	24.90	23.99
Price / Sales	N/A	6.98	527.78	108.89
Price / Cash	N/A	16.83	44.82	54.51
Price / Book	0.13	3.21	10.79	6.50
Net Income	-$19.39M	$226.25M	$3.56B	$336.88M
7 Day Performance	-4.61%	-1.89%	1.00%	-0.14%
1 Month Performance	-27.12%	-3.72%	0.42%	0.77%
1 Year Performance	-94.13%	-1.12%	29.70%	28.49%

GlucoTrack Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GCTK GlucoTrack	0.1808 of 5 stars	$0.36 +0.1%	N/A	-94.2%	$2.28M	N/A	N/A	5
MBAI Check-Cap	0.4229 of 5 stars	$1.36 flat	N/A	N/A	$9.91M	N/A	N/A	80
SINT Sintx Technologies	2.8445 of 5 stars	$2.08 -3.7%	$9.33 +348.7%	-37.5%	$9.33M	$1.02M	N/A	40
QNRX Quoin Pharmaceuticals	1.1851 of 5 stars	$4.62 +3.6%	N/A	-62.1%	$8.96M	N/A	N/A	4	News Coverage Gap Up
ALUR Allurion Technologies	1.4855 of 5 stars	$0.58 -1.7%	$3.00 +417.2%	-98.4%	$8.70M	$17.21M	N/A	501

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GCTK) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GlucoTrack (GCTK) Competitors

GCTK vs. MBAI, SINT, QNRX, ALUR, and NXL

How does GlucoTrack compare to Check-Cap?

Summary

How does GlucoTrack compare to Sintx Technologies?

Summary

How does GlucoTrack compare to Quoin Pharmaceuticals?

Summary

How does GlucoTrack compare to Allurion Technologies?

Summary

How does GlucoTrack compare to Nexalin Technology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GCTK vs. The Competition

GlucoTrack Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GlucoTrack (GCTK) Competitors

GCTK vs. MBAI, SINT, QNRX, ALUR, and NXL

How does GlucoTrack compare to Check-Cap?

Does the media prefer GCTK or MBAI?

Is GCTK or MBAI more profitable?

Do analysts rate GCTK or MBAI?

Which has higher valuation and earnings, GCTK or MBAI?

Which has more volatility and risk, GCTK or MBAI?

Do insiders & institutionals have more ownership in GCTK or MBAI?

Summary

How does GlucoTrack compare to Sintx Technologies?

Do analysts prefer GCTK or SINT?

Does the media refer more to GCTK or SINT?

Do insiders and institutionals hold more shares of GCTK or SINT?

Is GCTK or SINT more profitable?

Which has higher earnings & valuation, GCTK or SINT?

Which has more risk & volatility, GCTK or SINT?

Summary

How does GlucoTrack compare to Quoin Pharmaceuticals?

Is GCTK or QNRX more profitable?

Which has more volatility & risk, GCTK or QNRX?

Do analysts prefer GCTK or QNRX?

Do insiders & institutionals hold more shares of GCTK or QNRX?

Which has stronger earnings and valuation, GCTK or QNRX?

Does the media prefer GCTK or QNRX?

Summary

How does GlucoTrack compare to Allurion Technologies?

Does the media prefer GCTK or ALUR?

Do analysts prefer GCTK or ALUR?

Is GCTK or ALUR more profitable?

Which has better valuation and earnings, GCTK or ALUR?

Do institutionals and insiders hold more shares of GCTK or ALUR?

Which has more risk and volatility, GCTK or ALUR?

Summary

How does GlucoTrack compare to Nexalin Technology?

Do institutionals and insiders believe in NXL or GCTK?

Does the media refer more to NXL or GCTK?

Which has more risk and volatility, NXL or GCTK?

Is NXL or GCTK more profitable?

Which has higher valuation and earnings, NXL or GCTK?

Do analysts rate NXL or GCTK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GCTK vs. The Competition

GlucoTrack Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools